CClinicalTrials.gg
WithdrawnNCT03936946Updated May 26, 2021

The 28 Day Challenge

An interventional study of Audio Content 1 and Audio Content 2 in Depression, Anxiety and Stress, sponsored by Stanford University. Withdrawn at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-05-26.

Sponsored by Stanford University · Not applicable, Interventional, and Treatment

Why this study was withdrawn
Resources not secured
Phase
Not applicable
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to determine how a 28 Day Challenge influences mental health and well-being. This is a blinded study. Participants both with and without depression and anxiety, will be included. A moderation analysis will be performed to see whether changes in depression after the intervention are a function of baseline depression and anxiety levels.

02

Conditions studied

  • Depression
  • Anxiety
  • Stress
  • Hope

Browse trials for

03

In context

Depression

8,057 studies on the registry are indexed under Depression; 1,641 are open to participants now.

Browse Depression studies →

Lead sponsor

Stanford University is the lead sponsor of 2,117 studies on the registry; 425 are open to participants now.

Of its 259 completed or terminated interventional studies of FDA-regulated products, 197 (76%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • English Fluency

Exclusion criteria

Exclusion Criteria:

  • Severe hearing impairment
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Group 1--October Start Audio Content 1

    This group will listen to audio content 1 daily for 28 days beginning in October, and then will receive no further intervention

    Behavioral: Audio Content 1

  • Other
    Group 2--November Start Audio Content 1

    This group will not be assigned to any interventions during the first month of the trial and will act as a passive control group at that time. They will be assigned to listen to audio content 1 daily for 28 days beginning in November.

    Behavioral: Audio Content 1

  • Sham comparator
    Group 3--October Start Audio Content 2

    This group will listen to audio content 2 daily for 28 days beginning in October, and then will receive no further intervention.

    Behavioral: Audio Content 2

Interventions

  • BehavioralAudio Content 1

    \~30 minute daily audio recordings of content 1 for 28 days

  • BehavioralAudio Content 2

    \~30 minute daily audio recordings of content 2 for 28 days

06

What researchers measure

Primary outcomes

  1. Change in Patient Heath Questionnaire-9 (PHQ-9)

    The PHQ-9 is a self-administered survey used for diagnosing depression and assessing depression severity. It measures each of the 9 DSM-IV/V diagnostic criteria for depression on a 0-3 scale. Depression Severity is measured as follows: 0 none, 1-4 minimal, 5-9 mild, 10-14 moderate, 15-19 moderately severe, 20-27 severe. Validity has been assessed against structured clinical interviews. PHQ-9 scores ≥10 exhibited a sensitivity of 88% and a specificity of 88% for major depression. DSM = The Diagnostic and Statistical Manual of Mental Disorders

    Time frame: Baseline, 1 months

  2. Change in Patient Heath Questionnaire-9 (PHQ-9)

    The PHQ-9 is a self-administered survey used for diagnosing depression and assessing depression severity. It measures each of the 9 DSM-IV/V diagnostic criteria for depression on a 0-3 scale. Depression Severity is measured as follows: 0 none, 1-4 minimal, 5-9 mild, 10-14 moderate, 15-19 moderately severe, 20-27 severe. Validity has been assessed against structured clinical interviews. PHQ-9 scores ≥10 exhibited a sensitivity of 88% and a specificity of 88% for major depression. DSM = The Diagnostic and Statistical Manual of Mental Disorders

    Time frame: Baseline, 3 months

  3. Change in Generalized Anxiety Disorder-7 (GAD-7)

    The GAD-7 is a self report-based survey that assesses generalized anxiety disorder and severity on a 7-item scale. Scores of 5, 10, and 15 are taken as the cut-off points for mild, moderate and severe anxiety, respectively. The GAD-7 was compared to diagnoses by mental health professionals. Using scores \>/= 10, It has sensitivity of 89% and specificity of 82%.

    Time frame: Baseline, 1 months

  4. Change in Generalized Anxiety Disorder-7 (GAD-7)

    The GAD-7 is a self report-based survey that assesses generalized anxiety disorder and severity on a 7-item scale. Scores of 5, 10, and 15 are taken as the cut-off points for mild, moderate and severe anxiety, respectively. The GAD-7 was compared to diagnoses by mental health professionals. Using scores \>/= 10, It has sensitivity of 89% and specificity of 82%.

    Time frame: Baseline, 3 months

  5. Change in Perceived Stress Scale-10 (PSS-10)

    The Perceived Stress Scale-10 (PSS-10) measures global perceived stress via self-report on a ten item scale. Scores on the PSS can range from 0 to 40 with higher scores indicating higher perceived stress. Total scores ranging from 0-13 would be considered low stress. Total scores ranging from 14-26 would be considered moderate stress. Total scores ranging from 27-40 would be considered high perceived stress.

    Time frame: Baseline, 1 months

  6. Change in Perceived Stress Scale-10 (PSS-10)

    The Perceived Stress Scale-10 (PSS-10) measures global perceived stress via self-report on a ten item scale. Scores on the PSS can range from 0 to 40 with higher scores indicating higher perceived stress. Total scores ranging from 0-13 would be considered low stress. Total scores ranging from 14-26 would be considered moderate stress. Total scores ranging from 27-40 would be considered high perceived stress.

    Time frame: Baseline, 3 months

07

Study locations

1 site
  • Stanford University
    Stanford, California 94305, United States
08

References and documents

Individual participant data

Plan to share: No — No current plan to share data

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 26, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03936946
Lead sponsor
Stanford University
Responsible party
Michael Snyder (Chairman and Professor of Genetics, Stanford University) — Principal investigator
First posted
May 3, 2019
Start date
Jun 10, 2020 (estimated)
Primary completion
Jul 10, 2020 (estimated)
Completion
Oct 10, 2020 (estimated)
Last update
May 26, 2021

Study contacts

Michasel Snyder, PhD
principal investigator · Stanford University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion